US4067971A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic composition
Assignee: Procter and Gamble Co
•
Filing: 1976-05-13
•
Granted: 1978-01-10
•
Expires: 1996-05-13
Abstract
Abstract Phosphonate compounds are employed in the treatment of hypoxias and ischemic tissue diseases.
Inventors
- 👤 Marion D. Francis
- 👤 Irwin Y. Rosenblum
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 23:09
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61P; A61P11/00; A61P13/00; A61P13/02; A61P15/00; A61P25/00; A61P25/28; A61P27/00; A61P27/02; A61P7/00; A61P7/06; A61P9/00; A61P9/08; A61P9/10
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
52 words
A process for treating tissue or organ damage in a human or lower animal caused by ischemia of that tissue or organ, comprising administering to said human or lower animal in need of such treatment sufficient organophosphonate compound characterized by more than one phosphonate moiety to alleviate said tissue or organ damage.
Claim 2
Dependent Claim
52 words
A process for treating tissue or organ damage in a human or lower animal caused by ischemia of that tissue or organ, comprising administering to said human or lower animal in need of such treatment sufficient organophosphonate compound characterized by more than one phosphonate moiety to alleviate said tissue or organ damage.
Claim 3
Dependent Claim
13 words
A process according to claim 1 wherein the organophosphonate compound is a diphosphonate.
Claim 4
Dependent Claim
14 words
A process according to claim 2 wherein the organophosphonate compound is a geminal diphosphonate.
Claim 5
Dependent Claim
28 words
A process according to claim 3 wherein the organophosphonate compound is a member selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.
Claim 6
Dependent Claim
17 words
A process according to claim 4 wherein the organophosphonate compound is a sodium salt of ethane-1-hydroxy-1,1-diphosphonic acid.
Claim 7
Dependent Claim
28 words
A process according to claim 3 wherein the organophosphonate compound is a member selected from the group consisting of methanediphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.
Claim 8
Dependent Claim
28 words
A process according to claim 3 wherein the organophosphonate compound is a member selected from the group consisting of methanedichlorodiphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.
Claim 9
Dependent Claim
66 words
A process according to claim 1 for protecting a tissue or organ in a human or lower animal against subsequent degeneration, necrosis and fibrosis following infarction of that tissue or organ, comprising administering to said human or lower animal suffering from said infarct sufficient organophosphonate compound characterized by more than one phosphonate moiety to protect said tissue or organ against said subsequent degeneration, necrosis and fibrosis.
Claim 10
Dependent Claim
13 words
A process according to claim 8 wherein the organophosphonate compound is a diphosphonate.
Claim 11
Dependent Claim
14 words
A process according to claim 9 wherein the organophosphonate compound is a geminal diphosphonate.
Claim 12
Dependent Claim
28 words
A process according to claim 10 wherein the organophosphonate compound is a member selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.
Claim 13
Dependent Claim
17 words
A process according to claim 11 wherein the organophosphonate compound is a sodium salt of ethane-1-hydroxy-1,1-diphosphonic acid.
Claim 14
Dependent Claim
28 words
A process according to claim 10 wherein the organophosphonate compound is a member selected from the group consisting of methanediphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.
Claim 15
Dependent Claim
28 words
A process according to claim 10 wherein the organophosphonate compound is a member selected from the group consisting of methanedichlorodiphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.
Claim 16
Dependent Claim
54 words
A process according to claim 8 for treating myocardial infarction in humans comprising administering to a human in need of such treatment a safe and effective amount of a geminal diphosphonate which is a member selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid, methanediphosphonic acid, methanedichlorodiphosphonic acid, and the pharmaceutically-acceptable salts and esters thereof.
References Cited (Backward Citations)
US3584125A
Cited
US3584124A
Cited
US3678164A
Cited
US3641246A
Cited
US3662066A
Cited
US3683080A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-01-09 | 1981-07-11 | 1982-01-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-01-09 | 1985-07-11 | 1986-01-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-01-09 | 1989-07-11 | 1990-01-10 | $7700.00 | Window Closed / Lapsed |